Evaluation of the Spectra Optia® Mononuclear Cell Collection Procedure

Multiple Myeloma Clinical Trial

Official title:

Evaluation of the Spectra Optia® Apheresis System Mononuclear Cell (MNC) Collection Procedure in Multiple Myeloma Patients

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01292486
• Other study ID #: BCT10-02
• Status: Completed
• Phase: N/A
• First received: February 2, 2011
• Last updated: April 24, 2013
• Start date: February 2011
• Est. completion date: December 2011

Study information

• Verified date: April 2013
• Source: Terumo BCT
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

The purpose of this investigation is to establish that hematopoetic stem cells collected on a new centrifugal blood separator, CaridianBCT's Spectra Optia Apheresis System, are able to reconstitute the hematopoetic systems of patients treated with myeloablative therapy, equivalent to hematopoetic cells harvested on the predicate COBE® Spectra platform.

Description:

This is a multi-center (3-5) single-arm study that will compare the performance of the Spectra Optia Apheresis System's MNC protocol to that of the historical performance of the COBE Spectra MNC protocol. In order to demonstrate the substantial equivalence of the two devices, a non-inferiority design will be used. The study will enroll patients with multiple myeloma who are to be treated with myeloablative chemotherapy, followed by bone-marrow rescue with an autologous peripheral blood stem-cell transplant. Peripheral blood stem cells will be collected using the Spectra Optia MNC protocol and re-infused following myeloablative chemotherapy.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 32
• Est. completion date: December 2011
• Est. primary completion date: November 2011
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Histologic confirmation of Multiple Myeloma

• Patients intended to be treated with myeloablative therapy and autologous hematopoetic stem-cell transplant within one month of stem-cell collection

• Patients whose stem-cell mobilization regimen includes G-CSF (granulocyte-colony stimulating factor)

• Males or non-pregnant females, who are 18 years of age or older

• Karnofsky score of =70%

Exclusion Criteria:

• Patients with pre-mobilization platelet count < 75,000/µL

• Patients who have received pelvic bone marrow irradiation as part of their conditioning therapy

• Patients who have had a previous hematopoetic stem-cell transplant

• Patients who have had a previous hematopoetic stem-cell collection failure

• Impaired cardiac function, as evidenced by left ventricular ejection fraction <40%.

• Impaired hepatic function, as evidenced by alanine transaminase >2.5 x normal

• Impaired pulmonary function as evidenced by diffusion capacity of the lung for carbon monoxide (adjusted for patient hematocrit, if indicated) or forced expiratory volume in 1 second <50% of predicted

• Impaired renal function, as evidenced by a creatinine clearance < 40 mL/min

• Impaired coagulation, as evidenced by a prothrombin time (PT) > twice normal

• Pregnancy or lactation

• Seropositivity for Human Immunodeficiency Virus-1/2, Hepatitis B Virus, or Hepatitis C Virus

• Documented bacterial or fungal infection that requires intravenous antibiotics to be started or continued while undergoing apheresis collection on the Spectra Optia device

• Subjects enrolled in study protocols that could affect number of CD34+ cells (pluripoten hematopoetic stem stells) collected or kinetics of neutrophil recovery

• Altered mental status, as evidenced by the inability to provide effective informed consent

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care

Related Conditions & MeSH terms

• Multiple Myeloma
• Neoplasms, Plasma Cell

Intervention

Device:
• Spectra Optia Apheresis System
In this study, the safety and effectiveness of the new device will be assessed in two ways. First, MNC collections in growth-factor mobilized cancer patients will be evaluated to confirm that the Spectra Optia is able to collect stem cells. Second, following stem-cell collection and transplant, the number of days required for the collected hematopoetic stem cells to engraft/recover will be compared with historical COBE Spectra engraftment/recovery data.

Locations

Country	Name	City	State
United States	Emory University	Atlanta	Georgia
United States	Duke University Medical Center	Durham	North Carolina
United States	Indiana University	Indianapolis	Indiana
United States	University of Utah	Salt Lake City	Utah

Sponsors (1)

Lead Sponsor	Collaborator
Terumo BCT

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Days Until Neutrophil Recovery Following Peripheral Blood Stem Cell Transplant Minus the Historical Median Day Until Recovery.	Neutrophil recovery is defined as the day on which the peripheral blood absolute neutrophil count exceeds 500/µL (ANC500)for the first of three consecutive measurements obtained on different days following transplant of peripheral blood stem cells in patients treated with myeloablative therapy for their underlying disease.; As this was a test of non-inferiority, the null hypothesis to be tested (H0) was that the difference between the observed day to neutrophil recovery and the historical median day of neutrophil recovery was greater than two days. At two of the enrolling sites, Duke and Emory Universities, the median day to ANC500 was 12, while at the other two sites, Indiana University and the University of Utah, it was 11 days. Consequently, in the equation below, site specific-historic medians were compared to the observed days to achieve ANC500. H0: D > |2|, where D = Observed median day of neutrophil recovery - Site specific historic median day of neutrophil recovery.	up to 28 days following transplant	Yes
Secondary	Days Until Platelet Recovery	The time to platelet recovery is defined as the day following stem-cell transplant (Day 0) on which the platelet count exceeds 20,000/µL, for the first of three consecutive measurements obtained on different days, without platelet transfusion support within the preceding 7 days.	up to 28 days following transplant	No
Secondary	CD34+ Cell Collection Efficiency.	Collection efficiency (CE) is defined as the percentage of any given cellular subset, processed by the system, that is collected from the subject.; CD34+ is a cell surface marker found on pluripotent hematopoeitic stem cells.	up to 7 days	No
Secondary	Mononuclear Cel (MNC) Collection Efficiency	Collection efficiency (CE) is defined as the percentage of any given cellular subset, processed by the system, that is collected from the subject.; Determination of collection efficiency depends on an estimate of the average concentration of target cells in the patient's blood. Because these cells are continuously being removed during the collection, and are undergoing variable replacement from the bone marrow, this estimate will not be completely accurate. Underestimation of the concentration of target cells processed can lead to collection efficiencies of greater than 100%.	up to 7 days	No
Secondary	Platelet Collection Efficiency	Platelet contamination of the cell product was measured as the platelet collection efficiency, that is, as the percent of platelets processed that were collected.	up to 7 days	No
Secondary	Hematocrit of MNC Product	The hematocrit of the collected product was used to quantitate Red Blood Cell (RBC) contamination.	7 days	No
Secondary	Granulocyte % of MNC Product	Granulocyte contamination of the MNC product was quantitated as the percent of total product White Blood Cells (WBC) that were segmented granulocytes or bands.	7 days	No